Patrick Forde, Professor at The Johns Hopkins University, shared on X:
“Enjoyed presenting the results of the BioNTech mRNA TAA Fixvac phase 1 trial, BNT116 +/- cemiplimab in advanced NSCLC at ENA26. Efficacy signals in 1st line frail patients and post prior PD1, ongoing cohorts including oncogene-driven tumors.”
See important takeaways from the presentation in the gallery.
You can also read:
BioNTech Shares Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy in Metastatic HPV16-Positive HNC

Other articles about ENA 2026 on OncoDaily.